Market capitalization | $14.71m |
Enterprise Value | $7.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.19 |
P/S ratio (TTM) P/S ratio | 4.58 |
P/B ratio (TTM) P/B ratio | 1.73 |
Revenue growth (TTM) Revenue growth | 164.30% |
Revenue (TTM) Revenue | $3.21m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Immuron Limited Sponsored ADR:
1 Analyst has issued a forecast Immuron Limited Sponsored ADR:
Jun '24 |
+/-
%
|
||
Revenue | 3.21 3.21 |
163%
163%
|
|
Gross Profit | 2.19 2.19 |
149%
149%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -5.65 -5.65 |
40%
40%
|
Net Profit | -4.55 -4.55 |
78%
78%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
Head office | Australia |
CEO | Steven Lydeamore |
Founded | 1994 |
Website | www.immuron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.